AST/KDIGO CMV Serostatus Risk Stratification
CMV Serostatus & Context
CMV Risk Stratification
Select donor/recipient serostatus for risk-based prophylaxis guidance.
Guidelines & Evidence
Verified
Last Review: 2026-07-17
When to Use
When to Use
To stratify CMV risk in solid organ transplant based on donor/recipient serostatus
To guide CMV prophylaxis strategy and duration
To determine appropriate CMV monitoring intensity post-transplant
To assess the need for CMV-specific interventions in the setting of rejection treatment
To counsel transplant candidates about CMV risk before listing
Risk Categories
D+/R- (donor seropositive, recipient seronegative) is the highest-risk serostatus combination, associated with 40-60% risk of symptomatic CMV disease without prophylaxis. D-/R+ carries intermediate risk due to recipient latent virus reactivation. D-/R- is lowest risk but recipients remain susceptible to primary infection.
How it Works
CMV Serostatus Risk Groups
| D+/R- | High Risk — Primary infection. No pre-existing immunity. Highest risk of CMV disease and indirect effects. |
| D+/R+ | Moderate Risk — Reinfection or superinfection with donor strain. Some pre-existing immunity. |
| D-/R+ | Moderate-Low Risk — Reactivation of latent recipient strain. Lower viral loads typically. |
| D-/R- | Very Low Risk — No CMV transmission expected. Risk from blood products or community exposure. |
Additional Risk Modifiers
01
Induction therapy with ATG/ALG: Increases risk across all serostatus groups by 2-4 fold
02
Rejection treatment: Anti-rejection therapy (especially ATG) increases CMV reactivation risk
03
Lung/small bowel/pancreas transplant: Higher CMV risk than kidney or liver transplant
04
Donor/recipient HLA matching and net immunosuppression level
Clinical Pearls
Prophylaxis vs. Preemptive Approach
Two strategies exist for CMV prevention. Prophylaxis: Universal antiviral administration (valganciclovir 900 mg daily) to all at-risk recipients for a fixed duration (3-12 months depending on organ and risk group). Preemptive therapy: Serial CMV PCR monitoring with antiviral initiation only when viral load exceeds a predefined threshold. Prophylaxis is preferred for D+/R- recipients and high-risk programs; preemptive therapy is an alternative for lower-risk groups with reliable monitoring infrastructure.
Valganciclovir Dosing
Standard dose: 900 mg daily (renally adjusted: 450 mg daily for CrCl 40-59; 450 mg every other day for CrCl 25-39)
Treatment dose (CMV disease): 900 mg twice daily, renally adjusted
Duration: 3 months (kidney, liver standard risk) to 12 months (lung, D+/R- heart, pancreas)
IV ganciclovir: Preferred for patients unable to take oral or with very high viral loads
Monitor for neutropenia — valganciclovir causes dose-dependent leukopenia in 15-30% of patients
Next Steps
Clinical Action by Risk Group
01
D+/R-: Valganciclovir prophylaxis 6-12 months. Weekly CMV PCR for first 3 months post-prophylaxis.
02
D+/R+: Valganciclovir prophylaxis 3-6 months. Biweekly PCR during prophylaxis.
03
D-/R+: Consider prophylaxis (3 months) or preemptive monitoring per centre protocol.
04
D-/R-: No CMV prophylaxis. HSV/VZV prophylaxis only (acyclovir). No routine CMV PCR needed.
05
06
After prophylaxis completion: Monitor for late-onset CMV disease (especially D+/R-) for 3 months.
The Evidence
AST IDCOP Guidelines
Cytomegalovirus in solid organ transplantation.
Razonable RR et al. • Am J Transplant.. 2013;13(Suppl 4):93–106. Comprehensive CMV management guidelines.
IMPACT Study
Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients (IMPACT trial).
Humar A et al. • Am J Transplant.. 2010;10(5):1228–1237. Demonstrated benefit of 200 vs. 100 days prophylaxis in D+/R-.
Origins & History
CMV in Transplantation
CMV was first recognised as a significant pathogen in transplant recipients in the 1960s-70s. The serostatus-based risk stratification was formalised in the 1980s with the advent of serologic testing. The modern era of CMV management began with the introduction of ganciclovir in the late 1980s and its oral prodrug valganciclovir in the 2000s, which transformed CMV from a major cause of post-transplant mortality to a largely manageable infection.
Last Comprehensive Review: 2026-07-17